GTBP Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

GT Biopharma Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerGTBP

Market Cap15.9M

Cash RunwayRunway < 6 months

Next Catalyst2031-01

Public Research Snapshot

GT Biopharma Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for AL-335 in Chronic Hepatitis C (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
GTB-5550	Solid Tumors May 14, 2026	n/a	Phase 1	Public pipeline row
GTB-3650	Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies	n/a	Phase 1	Public pipeline row
AL-335	Chronic Hepatitis C	n/a	Phase 2	Public pipeline row
GTB-3550 TriKE® Phase I	n/a	n/a	Phase 1 \| Phase 2	Public pipeline row
AL-611	Hepatitis C	n/a	Phase 1	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2031-01	GTB-5550	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03253471	Phase 1	TERMINATED	24	2017-09-18
NCT02569710	Phase 2	COMPLETED	161	2018-05-11
NCT03214666	Phase 1 \| Phase 2	TERMINATED	12	2021-08-02
NCT07541573	Phase 1	RECRUITING	175	2031-01

Scientific Context

literature_publication | Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.
literature_publication | Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.
literature_publication | Biomarker study of pembrolizumab in patients with advanced rare cancers.
literature_publication | Antibody-drug conjugates in breast cancer: Progress and future directions.
literature_publication | Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Want the full GTBP research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.